Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels (EXACT-HF)

This study has been completed.
Information provided by (Responsible Party):
Duke University Identifier:
First received: September 30, 2009
Last updated: July 7, 2014
Last verified: July 2014

The purpose of this study is to determine whether allopurinol is effective in relieving symptoms of patients with heart failure and high blood uric acid levels.

Condition Intervention Phase
Heart Failure
Elevated Serum Uric Acid
Drug: allopurinol
Drug: sugar pill
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients

Resource links provided by NLM:

Further study details as provided by Duke University:

Primary Outcome Measures:
  • A composite clinical endpoint (CCE) that classifies subject's clinical status as improved, worsened, or unchanged. [ Time Frame: 24 Weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in quality of life (KCCQ). [ Time Frame: 12 and 24 weeks ] [ Designated as safety issue: No ]
  • Change in submaximal exercise capacity (6-MWT) [ Time Frame: 12 and 24 weeks ] [ Designated as safety issue: No ]

Enrollment: 253
Study Start Date: May 2010
Study Completion Date: June 2014
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: allopurinol
Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
Drug: allopurinol
Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
Placebo Comparator: sugar pill
Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
Drug: sugar pill
Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • NYHA class II-IV heart failure due to ischemic or non-ischemic cardiomyopathy.
  • Left ventricular ejection fraction ≤ 40% by echocardiography- Heart failure symptoms for 3 months despite standard treatment.
  • Serum uric acid level ≥ 9.5 mg/dl.
  • At least one of the following additional markers of increased risk: Hospitalization, ER visit or urgent clinic visit for heart failure requiring IV diuretics within the previous 12 months; Left ventricular ejection fraction ≤ 25; B-type natriuretic peptide level > 250 pg/ml

Exclusion Criteria:

  • Hypertrophic or restrictive cardiomyopathy, constrictive pericarditis, biopsy-proven myocarditis, severe stenotic valvular disease, or complex congenital heart disease.
  • Acute coronary syndrome, PCI or CABG within 3 months.
  • Current ventricular assist device or ventricular assist device or heart transplant likely within the next 6 months.
  • Uncontrolled hypertension (i.e., SBP > 170 mm Hg or DBP > 110 mm Hg)
  • Serum creatinine > 3 mg/dL or estimated GFR < 20 ml/min.
  • Evidence of active hepatitis with ALT and AST greater than 3x normal.
  • Any condition other than HF which could limit the ability to perform a 6-minute walk test
  • Any diseases other than HF which are likely to alter the patient's global perception of status or quality of life over a period of 6 months.
  • Receiving treatment with allopurinol currently or within 30 days, or having symptomatic hyperuricemia which requires treatment with allopurinol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00987415

United States, Georgia
Morehouse School of Medicine
Atlanta, Georgia, United States
United States, Massachusetts
Harvard University
Boston, Massachusetts, United States
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States
United States, Ohio
University Hospitals-Case Medical Center
Cleveland, Ohio, United States, 44106
United States, Texas
Baylor College of Medicine
Houston, Texas, United States
United States, Utah
Univ. of Utah Health Sciences Center
Salt Lake City, Utah, United States
United States, Vermont
University of Vermont
Burlington, Vermont, United States
University of Montreal
Montreal PQ, Canada
Sponsors and Collaborators
Duke University
Study Chair: Eugene Braunwald, MD Harvard University
Study Director: Alice Mascette, MD National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Adrian Hernandez, MD Duke University
  More Information

Additional Information:
No publications provided by Duke University

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Duke University Identifier: NCT00987415     History of Changes
Other Study ID Numbers: Pro00020011, 5U10HL084904
Study First Received: September 30, 2009
Last Updated: July 7, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Enzyme Inhibitors
Gout Suppressants
Antirheumatic Agents
Therapeutic Uses
Free Radical Scavengers
Protective Agents
Physiological Effects of Drugs processed this record on September 18, 2014